Virus that Causes Mono (EBV) Linked to Nasopharynx Cancer; CBCD Reviews Medical Studies

“Infected with the EBV virus? We recommend taking Novirin or Gene-Eden-VIR.” – Greg Bennett, CBCD

The Epstein Barr Virus (EBV) is directly linked to nasopharyngeal (or nasopharynx) cancer (NPC), one of the most common cancers that affect the uppermost region of the throat behind the nose. In fact, some doctors believe that targeting EBV, instead of radiotherapy (radiation therapy), may be the most effective treatment method for NPC. For example, Dr. Radha Raghupathy, MD and colleagues wrote that “The use of targeted therapies against EBV as stand-alone or adjunctive treatments is being explored.” (1) This is because the latent form of EBV, where the virus only replicates on a small scale, causes cancer. Dr. Radha Raghupathy, MD and colleagues are from the Partner State Key Laboratory of Oncology in South China.

The Center for the Biology of Chronic Disease (CBCD) therefore recommends that individuals infected with EBV take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against EBV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with EBV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2) In addition, this natural antiviral was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose were chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Dr. Raghupathy further wrote that “We are in an exciting era in the history of NPC. Basic scientific knowledge of EBV and NPC carcinogenesis is being rapidly translated into clinical practice. The development of EBV-based screening tools, EBV-directed therapies … are on the horizon.” (1) The CBCD is happy to see that the medical community is beginning to develop cancer therapies that target latent viruses. This is consistent with Dr. Hanan Polansky’s discovery of the role of latent viruses in cancer.

The Mayo Clinic says that “It isn’t clear why some people with all the risk factors (for NPV) never develop cancer, while others who have no apparent risk factors do.” (3)

Dr. Polansky’s book provides an answer. EBV chronically infects about 95% of the adult population, with virus usually present in B cells in a latent stage. According to Dr. Polansky, and his book “Microcompetition with Foreign DNA and the Origin of Chronic Disease,” people develop cancer when the number of latent viruses passes a certain threshold. One of the reasons for an increase in the number of latent viruses is a weak immune system. The CBCD offers a free download of Dr. Polansky’s book to those who are interested in reading it. It can be downloaded here: https://www.cbcd.net/Book.php (4)

What standard treatments are available for EBV infections?

“A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans.” (2) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and Novirin.

In light of the above information, the CBCD recommends that individuals infected with the Epstein Barr Virus (EBV) take Novirin or Gene-Eden-VIR.

Click to read more about Novirin and EBV, or Gene-Eden-VIR and EBV.

References:

(1)   Raghupathy R, Hui EP, Chan AT. Epstein-barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic. Am Soc Clin Oncol Educ Book. 2014;34:149-53.

(2)   Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 https://dx.doi.org/10.4236/pp.2013.46A001

(3)   May Clinic – Diseases and Conditions Nasopharyngeal Carcinoma

(4)   Polansky, H. Microcompetition with Foreign DNA and the Origin of Chronic Disease. 2003 CBCD

About CBCD

About CBCD

The Center for the Biology of Chronic Disease (https://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c) 3 of the IRS tax code. The center’s mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases. The CBCD first published Dr. Hanan Polansky’s highly acclaimed “Purple” book, entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” in 2003. In this book, he explains how foreign DNA fragments can cause many major diseases. The book has been read by more than 5,000 scientists around the world, and has been reviewed in more than 20 leading scientific journals. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.